APHRIA: Model update post Q2 results | BUY | CAD6.5 vs. CAD12.4 (+16%)
APHRIA - BUY | CAD6.5 vs. CAD12.4 (+16%)Model update post Q2 results
Lowering guidance
Oversupply will keep a lid on prices
Cash building to make move to a US consumer brand
Aphria is engaged in the production, supply and sale of medical cannabis in Canada. Co.'s medical cannabis is 100% greenhouse grown and comes in a range of products such as capsules, oral solutions, syringes and vaporizers. Co.'s cannabis capsules contain a precise dose of active cannabinoids in the form of purified cannabis oil. Co.'s oral solution contains purified cannabis oil in a liquid form. Co.'s syringe products are versatile and can be consumed in various forms, including orally or heated at a high temperature. Co.'s single-unit vaporizer cartridges are pre-filled with purified cannabis oil made from cannabis plant extract and natural terpenes.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.